Skip to content
DataLookout
Menu

NCT05515029

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

StatusUnknown
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2023); last known: Active, Not Recruiting
  2. Notable Primary completion date: Aug 15, 2025 to Aug 15, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 50 to confirmed 56
    • Site details revised
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Estimate the probability of developing acute GVHD stage II-IV after HSCT
Timeframe: evaluation period is 120 days after HSCT
severe (3-5 degrees) side effects of conditioning
Timeframe: evaluation period is 30 days after HSCT

Secondary (5)

event free survival
transplantation-associated mortality
relapse free survival
pathogen-specific immunoreconstitution
reactivation of CMV

Arms and interventions

GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab,calcineurin inhibitorExperimental

Combination products: GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor

Sites

1 site in 1 country

  • Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and ImmunologyMoscow, Samory-Mashela,1, Russia